Policy & Regulation
Zymeworks and Celgene expand Azymetric platform collaboration agreement
25 April 2018 -

Canada-based Zymeworks stated that Celgene has exercised its right to expand its collaboration agreement for the research, development, and commercialisation of bispecific antibody therapeutics using the former's Azymetric platform, it was reported yesterday.

According to the terms of the original collaboration agreement signed in 2014, which allowed Celgene to research and develop multiple bispecific antibodies based on the Azymetric platform, Celgene has now exercised its right to increase the number of potential products it can develop and commercialise from eight to ten, and extended the research program term by two years.

Zymeworks will receive an expansion fee and is now eligible to receive up to USD164m in development and commercial milestones for each of up to 10 products plus royalties on worldwide sales. In total, Zymeworks is now eligible to receive up to USD1.64bn in future payments for the entire collaboration.



Related Headlines